Arcus Biosciences established a collaboration with Bristol-Myers Squibb and discussed study plans with the FDA on August 1, 2026.

The entities involved

• FDA →
  • Abbott Laboratories faces an FDA recall classification of its sensors, while Ken Fisher and Donald Trump engage in stock transactions.01:40
  • Litigation regarding FDA approval process.Mon 22:49
• Arcus Biosciences →

  biopharmaceutical company

  Nothing else this week.

• Bristol-Myers Squibb →

  American pharmaceutical company

  • Bristol-Myers Squibb and Özlem Türeci presented late-stage oncology pipeline data and joint development activity in Mainz.Mon 13:24
  • Companies are pouring billions into protein degraders, a drug class that has received FDA approval and is being discussed by ASCO.Thu 17:40

Related events

• FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.Aug 28
• Zenith collaborates with Harvard researchers on clinical studies, receiving FDA clearance for the trial.Oct 8
• EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.Jun 8
• Arise is seeking FDA approval for a drug as of October 7, 2026.Oct 7
• Research advances have led to the approval of new therapies by the FDA.Thu 17:16